GlaxoSmithKline
GlaxoSmithKline (GSK plc) is a UK-headquartered global biopharmaceutical company that develops and commercializes specialty medicines, vaccines, and general medicines across respiratory, oncology, HIV, and infectious diseases, serving patients, healthcare providers, and governments in 70 countries with FY2025 turnover of £32.7 billion.
- Company typePublic
- Founded2000
- HeadquartersLondon, United Kingdom
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What GlaxoSmithKline does
GlaxoSmithKline (GSK plc) is a UK-headquartered, publicly traded biopharmaceutical company (NYSE/LSE: GSK) that discovers, develops, and commercializes specialty medicines, vaccines, and general medicines across four therapeutic areas: respiratory/immunology/inflammation, oncology, HIV, and infectious diseases. Following the 2022 demerger of its consumer healthcare business into Haleon plc, GSK operates as a focused biopharma with FY2025 group turnover of £32.7 billion (CER growth 7%), 66,800 employees, 33 manufacturing sites, and commercial presence in 70 countries; HIV is channeled primarily through majority-owned ViiV Healthcare (Pfizer and Shionogi as minority shareholders).
The company's portfolio is built around proprietary technology platforms including MAPS (Multiple Antigen Presentation System) vaccine technology acquired via Affinivax, antibody-drug conjugates (ADCs) such as Blenrep, functional genomics and human-genetics-driven target identification (2x higher clinical success rate for genetically-identified targets), and AI/ML-driven drug discovery accelerated by a Cerebras wafer-scale compute installation that delivers 748x faster molecular modeling versus the Frontier supercomputer. The pipeline contains 58 medicines and vaccines in development, with 2025 milestones including 5 FDA approvals, 7 positive Phase III readouts, and 15 filings/approvals; revenue is split between specialty medicines (>30% of sales), vaccines (389 million doses delivered in 2025, 99 million to Gavi), and general medicines (~one-third of sales), distributed via specialty pharmacy, retail pharmacy, hospital systems, and government public health procurement.
GSK's go-to-market combines enterprise field sales targeting oncologists, pulmonologists, HIV specialists, and infectious disease specialists across 70 markets, with channel partnerships for general medicines through retail pharmacy and government procurement via Gavi and national immunization programs. Pricing is volume/contract-based for vaccines and premium/subscription-based for specialty biologics; FY2025 R&D investment was £6.6 billion (approximately 20% of revenue), and the company executed 14 new partnerships and acquisitions in 2025, including the announced $10.6 billion Nuvalent oncology acquisition — the first major deal under CEO Luke Miels.
GlaxoSmithKline firmographics
Firmographics- Name
- GlaxoSmithKline
- Legal name
- GSK plc
- Website
- https://gsk.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- GlaxoSmithKline (GSK plc) is a UK-headquartered global biopharmaceutical company that develops and commercializes specialty medicines, vaccines, and general medicines across respiratory, oncology, HIV, and infectious diseases, serving patients, healthcare providers, and governments in 70 countries with FY2025 turnover of £32.7 billion.
- Ownership category
- akta.pro rank
GlaxoSmithKline industry classification
Industry- Product category
- Biopharmaceuticals (Pharmaceuticals & Vaccines)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where GlaxoSmithKline is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices10 records
Markets served
GlaxoSmithKline business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Specialty Medicines: Specialty medicines for asthma, cancer, HIV, and autoimmune diseases command premium pricing and represent over 30% of GSK's sales. Includes biologic therapies like Benlysta and Ojjaara.
- Vaccines: Portfolio of vaccines spanning infectious diseases from birth through adulthood. GSK delivers hundreds of millions of vaccine doses annually, including 389 million doses in 2025 and 99 million critical vaccine doses to Gavi for lower-income countries.
- General Medicines: General medicines including inhalers for asthma and COPD, antibiotics, and other primary care treatments distributed globally through pharmacies and healthcare systems. Represents approximately one-third of GSK's sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Specialty medicines with premium pricing for chronic conditions |
| Unit Pricing | Annual | Vaccines with政府采购 and retail channels |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels8 records
GlaxoSmithKline product offering
Product offeringCore offering
GSK is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines and vaccines across three product groups: Specialty Medicines (asthma, cancer, HIV, autoimmune diseases such as lupus; >30% of 2025 sales), Vaccines (broadest portfolio in the industry, 389 million doses delivered in 2025), and General Medicines (inhalers for asthma/COPD, antibiotics; ~1/3 of 2025 sales). It operates 33 manufacturing sites and a sales-led commercial model reaching 70 countries.
Product overview
GSK is a focused biopharma company that discovers, develops, and delivers medicines and vaccines to create value for patients and shareholders. The company operates across three main product categories: Specialty Medicines (preventing and treating asthma, cancer, HIV, and autoimmune diseases like lupus, generating >30% of sales with products including Benlysta, Ojjaara, Blenrep, and acquired assets like HS235, AIO-001, and Camlipixant), Vaccines (one of the broadest portfolios in the industry delivering hundreds of millions of doses annually including Shingrix and MAPS pneumococcal vaccines), and General Medicines (inhalers for asthma and COPD, antibiotics reaching people in 100+ countries). The pipeline spans four core therapeutic areas: respiratory/immunology/inflammation, oncology, HIV, and infectious diseases.
Differentiator
Problem solved
Functional benefit
Brands
- ViiV Healthcare: Joint venture with Pfizer and Shionogi focused exclusively on HIV treatment and prevention.
Products and services
- Benlysta (belimumab)
- Shingrix
- Calpol
- Ojjaara (momelotinib)
- Blenrep
- Blupeja
Quantifiable outcome
- 2x higher probability of clinical success using genetically-identified targets
- +4 more outcomes
Companies that use GlaxoSmithKline
Customer profileNamed customers7 records
Segments7 records
Ideal customer profiles4 records
GlaxoSmithKline technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
GlaxoSmithKline partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- NuvalentcoreGSK agreed to acquire Nuvalent for $10.6 billion (40% premium), acquiring two late-stage cancer drugs expected to receive FDA approval decisions in 2026. Deal funded through debt and cash reserves, GSK's first major acquisition under CEO Luke Miels.
- BiovacmajorBiovac retained R5.3 billion contract to supply Hexaxim six-in-one vaccine to South African government for three-year tender starting in 2027. Biovac also won contracts for BCG and measles-rubella vaccines supporting local vaccine manufacturing and export plans.
- Pfizer, AstraZeneca, Abbott, SanofiminorMajor pharmaceutical companies including GSK identified as key players in global pediatric healthcare market, collectively dominating the competitive landscape.
- 35PharmamajorGSK agreed to acquire Canadian biotech 35Pharma for $950 million to develop HS235, an investigational activin/BMP signaling pathway inhibitor for pulmonary hypertension. HS235 has completed Phase 1 and is positioned as next-generation versus Merck's Winrevair.
- IDRxminorUK-based GSK acquired US biopharmaceutical firm IDRx, Inc. to strengthen its specialty pharmaceuticals division and enhance targeted drug development capabilities.
- Aiolos BiocoreGSK announced acquisition of Aiolos Bio for $1 billion plus up to $400 million in milestone payments, gaining access to Aiolos' phase II-ready monoclonal antibody AIO-001 targeting TSLP pathway for respiratory and inflammatory conditions.
- BELLUS HealthmajorGSK agreed to acquire Canadian biopharmaceutical company BELLUS Health for $2 billion to strengthen portfolio in speciality medicines and respiratory products, particularly with camlipixant for treating refractory chronic cough.
- Vir BiotechnologyminorPartnership to advance COVID-19 and coronavirus treatments combining GSK's resources with Vir Biotechnology's antibody platform expertise.
- AffinivaxcoreGSK completed acquisition of Affinivax, a Boston-based biopharmaceutical company, for $2.1 billion plus potential milestone payments. Acquisition includes development of next-generation pneumococcal vaccines using MAPS technology, with candidates in clinical trials including breakthrough therapy designation by FDA.
- Sierra OncologymajorGSK completed acquisition of Sierra Oncology for approximately $1.9 billion, acquiring late-stage drug momelotinib for myelofibrosis with anemia, strengthening GSK's oncology portfolio.
- Ionis PharmaceuticalscoreCo-development partnership for bepirovirsen, a hepatitis B treatment co-developed by Ionis and GSK. Positive Phase 3 data showed 19% functional cure rate versus 0% on standard of care. FDA granted Priority Review with PDUFA date of October 26, 2026. GSK projects over £2 billion in peak sales.
- ViiV HealthcarecoreUnique partnership with Pfizer formed in 2009 (Shionogi joined in 2012) to create ViiV Healthcare, a company exclusively dedicated to treating and preventing HIV. GSK holds majority ownership with Pfizer and Shionogi as shareholders. ViiV has a portfolio of sixteen HIV treatments and preventative drugs with ambition to end the HIV epidemic.
Scale indicators19 records
Recent moves7 records
Expansion highlights8 records
GlaxoSmithKline competitors and assessment
Company assessmentDirect peers
- Roche: Global biopharma leader in oncology and diagnostics with overlapping ADC and targeted-therapy portfolios; competes head-to-head with GSK's oncology launches including Blenrep.
- Pfizer: Global biopharmaceutical company with overlapping therapeutic areas in oncology, vaccines, respiratory, and infectious diseases; Pfizer is also a partner in ViiV Healthcare alongside GSK.
- AstraZeneca: UK-headquartered peer competing across oncology, respiratory, and vaccines, with similar ADC and biologics strategies and a comparable global commercial footprint.
- Merck & Co. Major pharma competitor in oncology and vaccines (Keytruda franchise, pneumococcal vaccines), overlapping with GSK's oncology ADC platform and MAPS pneumococcal pipeline.
- Novartis: Swiss biopharma peer with comparable specialty-medicine focus areas (oncology, immunology) and similar post-divestiture reshaping (Sandoz spin-off).
- Sanofi: European peer with vaccines, specialty care, and respiratory franchises; competes with GSK in influenza vaccines, Dupixent-adjacent immunology, and rare disease.
- Bristol Myers Squibb: Specialty biopharma peer with oncology and immunology focus; competes in hematology (Ojjaara vs myelofibrosis rivals) and ADCs/IO combinations.
- Eli Lilly: Global biopharma peer with growing immunology and oncology presence; overlaps with GSK's autoimmune (Benlysta) and oncology ADC strategies.
- AbbVie: Specialty biopharma peer with immunology, oncology, and neuroscience focus; competes with GSK in immunology and ADC/oncology pipelines.
Broad incumbents
- Johnson & Johnson: Diversified healthcare conglomerate whose Innovative Medicine segment competes with GSK in oncology, immunology, and pulmonary hypertension; broader portfolio than GSK's focused biopharma scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights6 records
Customer concentration
GlaxoSmithKline social profiles
Digital presenceGlaxoSmithKline compliance and trust
Trust signalCompliance5 records
GlaxoSmithKline financial estimates
Financial estimateRevenue estimate
Valuation estimate
GlaxoSmithKline leadership team
Management profileNumber of profiles
Profiles21 records
GlaxoSmithKline subsidiaries and ownership
Company hierarchySubsidiaries8 records
GlaxoSmithKline funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GlaxoSmithKline M&A and investment
M&A and investmentM&A29 records
Investments29 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GlaxoSmithKline
What does GlaxoSmithKline do?
GSK is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines and vaccines across three product groups: Specialty Medicines (asthma, cancer, HIV, autoimmune diseases such as lupus; >30% of 2025 sales), Vaccines (broadest portfolio in the industry, 389 million doses delivered in 2025), and General Medicines (inhalers for asthma/COPD, antibiotics; ~1/3 of 2025 sales). It operates 33 manufacturing sites and a sales-led commercial model reaching 70 countries.
Is GlaxoSmithKline a public or private company?
GlaxoSmithKline is a public company. It is classified as public and is currently operating.
When was GlaxoSmithKline founded?
GlaxoSmithKline was founded in 2000. It employs 5,001 to 10,000 people.
Where is GlaxoSmithKline based?
GlaxoSmithKline is headquartered in London, United Kingdom, in the Europe region.
How does GlaxoSmithKline make money?
Three revenue lines are on record. Specialty Medicines are the primary driver. The others are vaccines and general Medicines.
Who are GlaxoSmithKline's main competitors?
Direct peers on record are Roche, Pfizer, AstraZeneca, Merck & Co., Novartis, Sanofi, Bristol Myers Squibb, Eli Lilly and AbbVie. Johnson & Johnson is listed as a broad incumbent.
Does GlaxoSmithKline have an API?
No public API is recorded for GlaxoSmithKline.
What industry is GlaxoSmithKline in?
GlaxoSmithKline's product category is Biopharmaceuticals (Pharmaceuticals & Vaccines). Its primary akta.pro industry code is HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325414 and its SIC code is 2836.